Cytogenetic Testing in Acute Leukemia. June 4, 2009
|
|
|
- Chrystal McCoy
- 7 years ago
- Views:
Transcription
1 Cytogenetic Testing in Acute Leukemia June 4, 2009
2 Objectives Describe genetic aspects of the 2008 WHO classification of acute leukemia Understand cytogenetic and molecular cytogenetic techniques Understand advantages and limitations of cytogenetic techniques
3 WHO 2008 Classification of Acute Leukaemia
4 AML and related precursor neoplasms AML with recurrent genetic abnormalities AML with myelodysplasia-related changes Therapy-related myeloid neoplasms Acute myeloid leukemia, NOS Myeloid sarcoma Myeloid proliferations related to Down syndrome Blastic plasmacytoid dendritic cell neoplasm
5 AML with recurrent genetic abnormalities AML with t(8;21)(q22;q22);(runx1/runx1t1) Good prognosis AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);cbfb-myh11 Good prognosis Acute promyelocytic leukemia with t(15;17)(q22;q12);pml-rara Good prognosis
6 t(8;21)
7 inv(16)
8 t(15;17)
9 AML with Recurrent Genetic Abnormalities (cont d) AML with t(9;11)(p22;q23);mllt3-mll AML with t(6;9)(p23;q34); DEK-NUP214 AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); PRN1-EVI1 AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 AML with mutated NPM1 AML with mutated CEBPA
10 AML with Recurrent Genetic Abnormalities (cont d) AML with t(9;11)(p22;q23);mllt3-mll Monocytic and myelomonocytic Intermediate prognosis, better than other MLL rearrangements
11 AML with Recurrent Genetic Abnormalities AML with t(6;9) Basophilia, multilineage dysplasia FLT3 mutation common Poor prognosis
12 t(6;9)
13 AML with Recurrent Genetic Abnormalities (cont d) AML with inv(3) or t(3;3) Platelet abnormalities Poor prognosis
14 AML with Recurrent Genetic Abnormalities (cont d) AML (megakaryoblastic) with t(1;22) Infants without Down syndrome Respond well to intensive chemotherapy
15 AML with gene mutations Not detectable by cytogenetics or FISH, but by PCR AML with mutated FLT3 AML with mutated NPM1 AML with mutated CEBPA Others: KIT, MLL, WT1, NRAS, KRAS
16 AML and related precursor neoplasms AML with recurrent genetic abnormalities AML with myelodysplasia-related changes Therapy-related myeloid neoplasms Acute myeloid leukemia, NOS Myeloid sarcoma Myeloid proliferations related to Down syndrome Blastic plasmacytoid dendritic cell neoplasm
17 AML with myelodysplasia- related changes 20% or more blood or bone marrow blasts Specific cytogenetic abnormalities Unbalanced, e.g. 7/del(7q), -5/del(5q), -13/del(13q), del(12p) Balanced, e.g. t(3;21), t(5;12), t(3;5) No abnormalities described in AML with recurrent genetic abnormalities
18 Therapy-related Myeloid Neoplasms Most have an abnormal karyotype
19 Myeloid proliferations related to Down syndrome Transient abnormal myelopoiesis Myeloid leukemia associated with Down syndrome; usually acute megakaryoblastic
20 Acute Leukemia of Ambiguous Lineage Acute undifferentiated leukemia Mixed phenotype acute leukemia with t(9;22) Poor prognosis Mixed phenotype acute leukemia t(v;11q23); MLL rearranged Poor prognosis Mixed phenotype acute leukemia, B/myeloid, NOS Mixed phenotype acute leukemia, T/myeloid, NOS Mixed phenotype acute leukemia, NOS-rare types Other ambiguous lineage leukemia
21 t(9;22)
22 t(11;19)
23 Precursor lymphoid neoplasms B lymphoblastic leukemia/lymphoma, NOS B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities T lymphoblastic leukemia/lymphoma
24 B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities B lymphoblastic leukemia/lymphoma with t(9:22)(q34;q11.2); BCR-ABL1 Poor prognosis B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged Poor prognosis B lymphoblastic leukemia/lymphoma with t(12;21) (p13;q22); TEL-AML1 (ETV6-RUNX1) Good prognosis
25 MLL
26 FISH t(12;21)
27 B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities (cont d) B lymphoblastic leukemia/lymphoma with hyperdiploidy good prognosis B lymphoblastic leukemia/lymphoma with hypodiploidy poor prognosis B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32);il3-igh B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1(TCF3-PBX1)
28 Hyperdiploid
29 Chromosomes 4, 10, 17
30 Cytogenetic Methods
31 Cell culture
32 Chromosome analysis
33 Karyotyping
34 Chromosome analysis Turnaround time 24hr + Sensitivity: variable; theoretically 14% Advantage: a good genome screen Disadvantages: labor-intensive, some malignant cells are difficult to find and to analyze
35 Genetic analysis Chromosome analysis Molecular analysis and molecular cytogenetics FISH, CISH Southern, PCR, sequencing, etc CGH and expression arrays
36 FISH principle
37 Fluorescence in situ hybridization (FISH)
38
39 Dual colour FISH - rearrangement
40 Interphase
41 FISH analysis Turnaround time: overnight after harvest Sensitivity: <1% to 8% Advantages: sensitivity, interphase analysis, small sample Disadvantages: need to know the abnormality being looked for; availability of probes
42 CGH and array CGH
43 Comparative genomic hybridization (CGH)
44 CGH and array CGH
45
46 CGH array
47 Array CGH data
48 Array CGH Widely used in developmental cytogenetics Research use in cancer Potential uses in acute leukemia Hyperdiploid pediatric ALL Other leukemias with imbalance
49 Children s Oncology Group (COG) Calgary cancer cytogenetics lab approved since 1999 Approval process Requirements Chromosome and FISH capability Abnormality rate >55% to maintain approval
50 COG analysis and submission All patients on COG acute leukemia protocols Flow cytometry information essential Chromosome analysis required for AML and ALL FISH analysis required for ALL: 4, 10, 17, t(9;22), MLL, t(12;21) Submit analysis data and images for central review
51 Other QA ACMG/CAP cytogenetic and FISH challenges include cancer images and slides for cancer FISH Rates of abnormality Failure rates
52
Acute leukemias and myeloproliferative neoplasms
Acute leukemias and myeloproliferative neoplasms GERGELY SZOMBATH SEMMELWEIS UNIVERSITY OF MEDICINE IIIRD. DEPARTMENT OF INTERNAL MEDICINE Basics of acute leukemia Neoplastic disease Cell of origin is
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
Basics of AML. Acute myeloid leukemia and related myeloid neoplasms: WHO 2008 brings us closer to understanding clinical behavior
Acute myeloid leukemia and related myeloid neoplasms: WHO 2008 brings us closer to understanding clinical behavior No conflicts of interest to disclose Steven Devine, MD The Ohio State University Common
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Arjan A. van de Loosdrecht, MD, PhD Department of Hematology VU University Medical Center VU-Institute of Cancer and Immunology
Clinical Use of Karyotype and Molecular Markers In Curing Acute Myeloid Leukemia
Clinical Use of Karyotype and Molecular Markers In Curing Acute Myeloid Leukemia Clara D. Bloomfield, M.D. Distinguished University Professor The Ohio State University Comprehensive Cancer Center, and
Cancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
CASE 2. Seven week old female infant presents with hepatosplenomegaly l and WBC 31.0k/mm 3, Hgb 9.2 g/dl, Plt 110k/mm 3 with 60% blasts
CASE 2 Seven week old female infant presents with hepatosplenomegaly l and WBC 31.0k/mm 3, Hgb 9.2 g/dl, Plt 110k/mm 3 with 60% blasts A bone marrow biopsy and aspirate were performed (photos provided).
Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.
1 2 3 4 The FAB assigns a cut off of 30% blasts to define AML and relies predominantly on morphology and cytochemical stains (MPO, Sudan Black, and NSE which will be discussed later). Subtypes of AML follow
APPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen
APPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen Outline Diagnosis Prognosis Treatment AML Elderly AML APL Future directions AML
Risk Stratification in AML. Michelle Geddes Feb 27, 2014
Risk Stratification in AML Michelle Geddes Feb 27, 2014 Objectives Outline the challenges in post-remission therapy for AML Review etiology of disease escape mechanisms from therapy Evaluate prognostic
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA Cytogenetics is the study of chromosomes and their structure, inheritance, and abnormalities. Chromosome abnormalities occur in approximately:
Leukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
Myelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Plasma Cell (Multiple) Myeloma
Myelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Plasma Cell (Multiple) Myeloma Hodgkin Lymphoma Overview Case Pathophysiology Diagnosis
Cytogenetics for the Rest of Us: A Primer
Cytogenetics for the Rest of Us: A Primer James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Diane Maia, M.D. Pathologist, Bon Secours Hampton Roads Case #1 78 y.o. lady seen
Flt3-ITD, NPM1 and CEBPα mutation detection in AML
Flt3-ITD, NPM1 and CEBPα mutation detection in AML a collaborative diagnostic assay setup Friedel Nollet, Ph.D., AZ Sint-Jan Brugge-Oostende AV Acute Myeloïd Leukemia AML subgroups (WHO2008 classification)
Oncology Best Practice Documentation
Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings
Project no. 261474 ENCCA. EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS. Network of Excellence. Deliverable Number: 9.
Project no. 261474 ENCCA EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS Network of Excellence Deliverable Number: 9.1 Title: Common guidelines for diagnostic approaches to leukemias Due
Oncologist. The. Pediatric Oncology. Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia
The Oncologist Pediatric Oncology Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia SOHEIL MESHINCHI, a ROBERT J. ARCECI b a Fred Hutchinson Cancer Research Center, University
Acute Myelogenous Leukemia Pre-HSCT Data
Instructions for Acute Myelogenous Leukemia Pre-HSCT Data (Form 2010) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the AML Pre-HSCT Data Form. E-mail
Pathology No: SHS-CASE No. Date of Procedure: Client Name Address
TEL #: (650) 725-5604 FAX #: (650) 725-7409 Med. Rec. No.: Date of Procedure: Sex: A ge: Date Received: Date of Birth: Account No.: Physician(s): Client Name Address SPECIMEN SUBMITTED: LEFT PIC BONE MARROW,
SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015
LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:
Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma
Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Updated April 2008 by Dr. Richard Wells* Updates: Minor changes only Introduction Acute lymphocytic leukemia (ALL) is a relatively
Manchester Cancer Haemato-oncology Pathway. Guidelines for the management of Acute Myeloid Leukaemia
Manchester Cancer Haemato-oncology Pathway Guidelines for the management of Acute Myeloid Leukaemia Dr Rowena Thomas Dewing Dr Eleni Tholouli Dr Mike Dennis Version 2.0 June 2015 Review date June 2018
Acute myeloid leukaemia (AML) in children
1 61.02 Acute myeloid leukaemia (AML) in children AML can affect children of any age, and girls and boys are equally affected. Leukaemia Acute myeloid leukaemia (AML) FAB classification of AML Causes of
Response Definition, Evaluation and Monitoring. Michele Baccarani
Response Definition, Evaluation and Monitoring Michele Baccarani European LeukemiaNet EVOLVING CONCEPTS IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA VENICE 8 9 MAY 2006 Response definition, evaluation
Hematologic Malignancies
Hematologic Malignancies Elizabeth A. Griffiths, MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan
Acute Myeloid Leukemia
CHAPTER Acute Myeloid Leukemia Kathryn Foucar, MD Definition 377 [18.2] Epidemiology and Pathogenesis 379 Kaaren Reichard, MD [18.3] Key Steps in the Diagnosis of AML 379 David Czuchlewski, MD [18.4] Blasts
ncounter Leukemia Fusion Gene Expression Assay Molecules That Count Product Highlights ncounter Leukemia Fusion Gene Expression Assay Overview
ncounter Leukemia Fusion Gene Expression Assay Product Highlights Simultaneous detection and quantification of 25 fusion gene isoforms and 23 additional mrnas related to leukemia Compatible with a variety
Boolean Implications Identify Wilms Tumor 1 Mutation as a Driver of DNA Hypermethylation in Acute Myeloid Leukemia
Boolean Implications Identify Wilms Tumor 1 Mutation as a Driver of DNA Hypermethylation in Acute Myeloid Leukemia Subarna Sinha PhD Department of Computer Science Principal Investigator: David Dill Daniel
Abstract. Bone marrow-level oxygen tension enables enhanced and sustained growth of 3 new pediatric acute lymphoblastic leukemia cell lines
Abstract Bone marrow-level oxygen tension enables enhanced and sustained growth of 3 new pediatric acute lymphoblastic leukemia cell lines Michael A. Sheard, Min Kang, Daniel Cabral, Joanne Lee, Lilia
March 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,
Dr. Daniel Duvall, Medical Officer Center for Medicare, Hospital and Ambulatory Policy Group Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Dr. Edith Hambrick,
Clinicopathologic Analysis of Acute Myeloid Leukemia in a Single Institution: Biphenotypic Acute Myeloid Leukemia May Not Be an Aggressive Subtype
ORIGINAL ARTICLE Clinicopathologic Analysis of Acute Myeloid Leukemia in a Single Institution: Biphenotypic Acute Myeloid Leukemia May Not Be an Aggressive Subtype Ming-Yuan Lee 1,4 *, Tran-Der Tan 2,
Childhood and Adolescent Lymphoid and Myeloid Leukemia
Childhood and Adolescent Lymphoid and Myeloid Leukemia Ching-Hon Pui, Martin Schrappe, Raul C. Ribeiro, and Charlotte M. Niemeyer Remarkable progress has been made in the past decade in the treatment and
Guidelines and Quality Assurance for Acquired Cytogenetics
Guidelines and Quality Assurance for Acquired Cytogenetics A common European framework for quality assessment for banded chromosome studies and molecular cytogenetic investigations of acquired abnormalities.
Leukemia Acute Myeloid (Myelogenous)
Leukemia Acute Myeloid (Myelogenous) What is acute myeloid leukemia? Cancer starts when cells in a part of the body begins to grow out of control and can spread to other areas of the body. There are many
Clinical Information Systems to Support Personalized Medicine at the Bedside
Clinical Information Systems to Support Personalized Medicine at the Bedside March 2012 Mia Levy, MD, PhD Director Cancer Clinical Informatics, Vanderbilt Ingram Cancer Center Assistant Professor of Biomedical
Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
Overview of Genetic Testing and Screening
Integrating Genetics into Your Practice Webinar Series Overview of Genetic Testing and Screening Genetic testing is an important tool in the screening and diagnosis of many conditions. New technology is
Protocol. Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia
Hematopoietic Stem-Cell Transplantation for Acute Myeloid (80126) Medical Benefit Effective Date: 07/01/14 Next Review Date: 05/16 Preauthorization Yes Review Dates: 04/07, 05/08, 05/09, 05/10, 05/11,
Prognostic markers in pediatric leukemia and mechanisms of KRAS-induced leukemogenesis
Prognostic markers in pediatric leukemia and mechanisms of KRAS-induced leukemogenesis Anna Staffas Department of Clinical Chemistry and Transfusion Medicine Institute of Biomedicine Sahlgrenska Academy
Acute myeloid leukemia (AML)
Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult
Therapy-related leukemia/myelodysplastic syndrome in multiple myeloma
Therapy-related leukemia/myelodysplastic syndrome in multiple myeloma KAZUHIKO NATORI DAISUK NAGASE SUSUMU ISHIHARA AKIKO YUKITOSHI TOYODA MOTOHIRO KATO YOSINORI FUJIMOTO YASUNOBU KURAISHI HARUKA IZUMI
Prognostic Value of Cytogenetic Findings in Adults With Acute Myeloid Leukemia
Progress in Hematology International Journal of HEMATOLOGY Prognostic Value of Cytogenetic Findings in Adults With Acute Myeloid Leukemia Krzysztof Mrózek,* Kristiina Heinonen, Clara D. Bloomfield Division
Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation
Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation Dr Ros Ganderton, Ms Kate Parratt, Dr Debbie Richardson, Dr Kim Orchard and Dr Liz Hodges Departments of Molecular Pathology
Ar Mino changes including adjustment of therapy algorithms
cute Myeloid Leukemia Updated April 2008 by Dr. Richard Wells* Updates: Ar Mino changes including adjustment of therapy algorithms Introduction Acute myeloid leukemia is a relatively uncommon cancer with
Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
Childhood Leukemia. Normal bone marrow, blood, and lymphoid tissue
Childhood Leukemia What is childhood leukemia? Cancer starts when cells start to grow out of control. Cells in nearly any part of the body can become cancer. To learn more about how cancers start and spread,
About B Cell Lymphomas Groupmeeting Klipp/Spang, December 09 2002 Dennis Kostka Max-Planck-Institute for Molecular Genetics Computational Molecular Biology Berlin 1 Overview Short History of Lymphoma Classification
CML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More
A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,
Project Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D
Phase I study using T cells expressing a CD123-specific chimeric antigen receptor and truncated EGFR for patients with relapsed or refractory acute myeloid leukemia Project Lead: Stephen Forman, M.D. PI:
Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time
Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care
Treating Minimal Residual Disease in Acute Leukemias: How low should you go?
Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Ramsie Lujan, Pharm.D. PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Pharmacotherapy Education and
Synopsis of Causation. Chronic Myeloid Leukaemia
Ministry of Defence Synopsis of Causation Chronic Myeloid Leukaemia Author: Dr M A Vickers, University of Aberdeen, Aberdeen Validator: Professor John Goldman, Hammersmith Hospital, London September 2008
GENETIC PROGNOSTIC FACTORS IN ACUTE MYELOID LEUKEMIA
GENETIC PROGNOSTIC FACTORS IN ACUTE MYELOID LEUKEMIA PhD dissertation Magdalena Renata Koszarska Eötvös Loránd University, Faculty of Science Doctoral School of Biology Classical and Molecular Genetics
Karyotyping, FISH, and PCR in Acute Lymphoblastic Leukemia. Competing or Complementary Diagnostics?
ORIGINAL ARTICLE Karyotyping, FISH, and PCR in Acute Lymphoblastic Leukemia Competing or Complementary Diagnostics? Louise Olde Nordkamp, BSc,* Clemens Mellink, PhD,w Ellen van der Schoot, MD, PhD,z and
The following chapter is called "Preimplantation Genetic Diagnosis (PGD)".
Slide 1 Welcome to chapter 9. The following chapter is called "Preimplantation Genetic Diagnosis (PGD)". The author is Dr. Maria Lalioti. Slide 2 The learning objectives of this chapter are: To learn the
Gene expression profiling in acute leukemias: New insights into biology and a global approach to the diagnosis of leukemia using microarray technology
Gene expression profiling in acute leukemias: New insights into biology and a global approach to the diagnosis of leukemia using microarray technology Dissertation an der Fakultät für iologie der Ludwig-Maximilians-Universität
Relative Risk (Sokal & Hasford): Relationship with Treatment Results. Michele Baccarani
Relative Risk (Sokal & Hasford): Relationship with Treatment Results Michele Baccarani European LeukemiaNet EVOLVING CONCEPTS IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA VENICE 8 9 MAY 2006 Disease risk
Treatment Recommendations for People Living with CML
Treatment Recommendations for People Living with CML Foreword by CML Workgroup Chronic myeloid leukaemia (CML) is a disease of the blood and bone marrow that results when there is a cancerous transformation
An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
Leukemia Research Foundation 2004-2005 Scientific Research Grant Recipients
Page 1 of 5 NEW INVESTIGATOR AWARDS Ioannis Aifantis, Ph.D. The University of Chicago, Chicago, IL $75,000.00 Cooperation of Notch and pre-tcr Signaling in the Induction of T Cell Leukemia The pre-t Cell
Malignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
Package golubesets. June 25, 2016
Version 1.15.0 Title exprsets for golub leukemia data Author Todd Golub Package golubesets June 25, 2016 Maintainer Vince Carey Description representation
Leukemia. Leukemia vs lymphoma The major types of leukemia are based on whether the disease is: Acute or chronic Lymphocytic or myeloid
Leukemia Leukemia vs lymphoma The major types of leukemia are based on whether the disease is: Acute or chronic Lymphocytic or myeloid Acute vs chronic leukemia rapid increase in immature blood cells.
6/20/2014. PART I: Plasma Cell Myeloma. Plasma Cells
MULTIPLE MYELOMA: THE TESTING, VALIDATION AND IMPLEMENTATION OF CELL SEPARATION TECHNOLOGY FOR IMPROVED PATIENT CARE Elizabeth Harper CG(ASCP), Binh Vo CG(ASCP), Joey Pena CG(ASCP), Denise Lovshe CG(ASCP),
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Leukaemia: Description A group of malignant disorders affecting: White blood cells (lymphocytes or leucocytes) Bone
Myelodysplasia. Dr John Barry
Myelodysplasia Dr John Barry Myelodysplasia Group of heterogenouus bone marrow disorders that are due to a defect in stem cells. Increasing bone marrow failure leading to quan>ta>ve and qualita>ve abnormali>es
Hematopathology VII Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, And Hairy Cell Leukemia
John L. Kennedy, M.D. UIC College of Medicine Associate Professor of Clinical Pathology M2 Pathology Course Lead Pathologist, VA Chicago Health Care System Lecture #43 Phone: (312) 569-6690 Thursday, November
Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA
Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia
Fluorescence in situ hybridisation (FISH)
Fluorescence in situ hybridisation (FISH) rarechromo.org Fluorescence in situ hybridization (FISH) Chromosomes Chromosomes are structures that contain the genetic information (DNA) that tells the body
NGS e malattie mieloproliferative
NGS e malattie mieloproliferative Matteo G Della Porta Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia Medical School, Pavia, Italy matteo@haematologica.org
MEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
What is acute myeloblastic leukaemia?
Acute Myeloblastic Leukaemia What is acute myeloblastic leukaemia? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines
Effect of lymphocyte count and AML prognosis. Hanahlyn Park. A thesis. submitted in partial fulfillment of the. requirements for the degree of
Effect of lymphocyte count and AML prognosis Hanahlyn Park A thesis submitted in partial fulfillment of the requirements for the degree of Master of Nursing University of Washington 2014 Committee: Kathleen
DNA Methylation in MDS/MPD/AML: Implications for application
DNA Methylation in MDS/MPD/AML: Implications for application James G. Herman, M.D. Professor of Oncology Evelyn Grollman Glick Scholar The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Disclosures
Myeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies
Myeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies Robert J. Arceci, M.D., Ph.D. King Fahd Professor of Pediatric Oncology Professor of Pediatrics, Oncology and
Acute Myeloid Leukemia
Acute Myeloid Leukemia Tom, AML survivor Revised 2011 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is committed to bringing
Acute Myeloid Leukemia
hematology Board Review Manual Statement of Editorial Purpose The Hospital Physician Hematology Board Review Manual is a study guide for fellows and practicing physicians preparing for board examinations
A Time Line Of Chronic Myeloid Leukemia
Chronic Myeloid Leukemia in 2011 An Update on Treatment and Monitoring Michael Deininger MD PhD Chief, Division of Hematology and Hematologic Malignancies M. M. Wintrobe Professor of Medicine A Time Line
MORPHOLOGY AND CYTOGENETICS IN ACUTE MYELOID LEUKEMIA - FOCUS ON MYELODYSPLASIA RELATED CHANGES
MORPHOLOGY AND CYTOGENETICS IN ACUTE MYELOID LEUKEMIA - FOCUS ON MYELODYSPLASIA RELATED CHANGES Elena-Cristina Selicean 1, Mariana Patiu 1,2, A. Cucuianu 1,2, Delia Dima 1, Minodora Dobreanu 3,4 1 ION
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
Update in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
Acute Myeloid Leukemia
Acute Myeloid Leukemia Introduction Leukemia is cancer of the white blood cells. The increased number of these cells leads to overcrowding of healthy blood cells. As a result, the healthy cells are not
6/5/10. Acute lymphoblastic leukemia Approaches to risk stratification. Improved Survival in Childhood ALL by Study Era WHO WILL BE CURED?
Estimated Survival Percentage 6/5/10 Acute lymphoblastic leukemia Approaches to risk stratification Mignon Loh, MD Associate Professor of Pediatrics University of California, San Francisco Improved Survival
Answering your questions on Chronic Myeloid Leukaemia (CML)
Answering your questions on Chronic Myeloid Leukaemia (CML) Your guide to understanding CML and Glivec (imatinib) treatment The information in this booklet is designed to help you understand chronic myeloid
Daiichi Sankyo to Acquire Ambit Biosciences
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
LEUCEMIA MIELOIDE ACUTA. A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova
LEUCEMIA MIELOIDE ACUTA A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova Impact of mutational analysis in AML C. Thiede Optimal acute myeloid leukemia therapy in 2012 H. Dombret Acquired
Acute Myeloid Leukemia
Acute Myeloid Leukemia Tom, AML survivor Support for this publication provided by Revised 2015 Pantone info: Sunesis text is 269 Sunesis swirl is 557 A Message from Louis J. DeGennaro, PhD President and
Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.
Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates
Secondary hematologic malignancies after chemotherapy. Sasha Stanton MD PhD February 14, 2014 Dr. Tony Blau Discussant
Secondary hematologic malignancies after chemotherapy Sasha Stanton MD PhD February 14, 2014 Dr. Tony Blau Discussant Case 1 Referral from Dr. Blau (Sibel) of a 60 yo woman 3 years out of therapy for her
The genetic screening of preimplantation embryos by comparative genomic hybridisation
Vol. 11, Suppl. 3 51 The genetic screening of preimplantation embryos by comparative genomic hybridisation Maria V Traversa 1, James Marshall, Steven McArthur, Don Leigh Genea, Sydney, Australia Received:
ACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
Acute Myeloid Leukemia
Acute Myeloid Leukemia Jeffrey E. Rubnitz, MD, PhD a, *, Brenda Gibson, MD b, Franklin O. Smith, MD c KEYWORDS Myeloid Leukemia Childhood Acute myeloid leukemia (AML) is a heterogeneous group of leukemias
The CML Guide Information for Patients and Caregivers
The CML Guide Information for Patients and Caregivers LEUKEMIA LYMPHOMA CHRONIC MYELOGENOUS LEUKEMIA MYELOMA Printing of this publication made possible by a grant from A Message from John Walter President
DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT
www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers
Stem Cell Transplantation for Acute Lymphoblastic Leukemia
Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic
EDUCATIONAL COMMENTARY - GRANULOCYTE FORMATION AND CHRONIC MYELOCYTIC LEUKEMIA
LEUKEMIA Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn CE Credits under Continuing Education
Chromosome Conference
ANNOUNCING The Fiftieth Annual Great Lakes DATES: May 17-18, 2012 LOCATION: 89 Chestnut Street, University of Toronto ACCOMMODATION: Conference rates are not available at the Metropolitan Hotel or at the
Comparative genomic hybridization Because arrays are more than just a tool for expression analysis
Microarray Data Analysis Workshop MedVetNet Workshop, DTU 2008 Comparative genomic hybridization Because arrays are more than just a tool for expression analysis Carsten Friis ( with several slides from